Danish Medicines Agency
Scandion Oncology når viktig milstolpe
I veckan kunde Scandion Oncology meddela att bolagets läkemedelskandidat SCO-101 fungerar i synergi med cancerterapin docetaxel i docetaxelresistenta cancerceller....
Scandion Oncology ready for phase II with SCO-101
Scandion Oncology’s candidate SCO-101 is being developed to...
